Literature DB >> 9866434

Prevalence of antimicrobial drug-resistant Streptococcus pneumoniae in Washington State.

P A Frick1, D J Black, J S Duchin, S Deliganis, W M McKee, T R Fritsche.   

Abstract

We conducted a survey to assess the prevalence and geographic distribution of antimicrobial drug resistance among invasive isolates of Streptococcus pneumoniae in Washington State. Sequential sterile-site pneumococcal isolates were submitted from 13 hospital laboratories between 1 October 1995 and 30 January 1997. We serotyped 275 isolates from adults and children and determined minimum inhibitory concentrations (MIC) for commonly used antimicrobial drugs. Data were abstracted from medical records to compare differences in outcome and risk factors for infection. Of the 275 isolates, 73 (26.5%) were nonsusceptible to one or more antimicrobial drugs. Penicillin-nonsusceptible pneumococci (PNSP, MIC > or = 0.1 microgram/ml) accounted for 42 (15.3%) of the 275 isolates including 4 (1.5%) resistant strains (MIC > or = 2 micrograms/ml). The 42 PNSP included serogroups 6, 9, 14, 19, and 23, all of which are represented in the 23-valent pneumococcal vaccine. PNSP were also nonsusceptible to trimethoprim/sulfamethoxazole (92.9%), erythromycin (38.1%), imipenem (28.6%), and ceftriaxone (23.8%). Forty-seven (17.1%) of the 275 isolates were multiple drug-nonsusceptible pneumococci (MDNSP). A significantly greater number of patients < or = 12 years of age were infected with MDNSP compared with those > 12 years. Prior use of antimicrobial drugs and an immunosuppressive disorder were risk factors for infection with PNSP. In summary, pneumococci nonsusceptible to penicillin and other antimicrobial drugs are prevalent among adults with invasive pneumococcal disease in Washington State. A large proportion of PNSP are resistant to other commonly used antimicrobial drugs. Local antibiotic susceptibility data should be considered when designing empiric treatment regimens.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9866434      PMCID: PMC1305404     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


  26 in total

Review 1.  Treatment of bacterial meningitis.

Authors:  V J Quagliarello; W M Scheld
Journal:  N Engl J Med       Date:  1997-03-06       Impact factor: 91.245

2.  Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study.

Authors:  G V Doern; A Brueggemann; H P Holley; A M Rauch
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

3.  The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: an update from the Centers for Disease Control and Prevention's Pneumococcal Sentinel Surveillance System.

Authors:  J C Butler; J Hofmann; M S Cetron; J A Elliott; R R Facklam; R F Breiman
Journal:  J Infect Dis       Date:  1996-11       Impact factor: 5.226

4.  Quantity and avidity of pneumococcal antibodies before and up to five years after pneumococcal vaccination of elderly persons.

Authors:  H B Konradsen
Journal:  Clin Infect Dis       Date:  1995-09       Impact factor: 9.079

5.  Serotypes and antibiotic susceptibilities of Streptococcus pneumoniae in Nairobi, Kenya.

Authors:  J Paul; J Bates; J Kimari; C Gilks
Journal:  J Infect       Date:  1996-03       Impact factor: 6.072

6.  Highlights of the French Antimicrobial Resistance Surveillance Project. French Study Group.

Authors:  Y Péan; F W Goldstein; M L Guerrier
Journal:  Diagn Microbiol Infect Dis       Date:  1996-08       Impact factor: 2.803

7.  Epidemiological features of and risk factors for infection by Streptococcus pneumoniae strains with diminished susceptibility to penicillin: findings of a French survey.

Authors:  J P Bédos; S Chevret; C Chastang; P Geslin; B Régnier
Journal:  Clin Infect Dis       Date:  1996-01       Impact factor: 9.079

8.  Predictive factors for invasive disease due to penicillin-resistant Streptococcus pneumoniae: a population-based study.

Authors:  J M Nava; F Bella; J Garau; J Lite; M A Morera; C Martí; D Fontanals; B Font; V Pineda; S Uriz
Journal:  Clin Infect Dis       Date:  1994-11       Impact factor: 9.079

9.  Minimizing the impact of drug-resistant Streptococcus pneumoniae (DRSP). A strategy from the DRSP Working Group.

Authors:  D B Jernigan; M S Cetron; R F Breiman
Journal:  JAMA       Date:  1996-01-17       Impact factor: 56.272

10.  The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta.

Authors:  J Hofmann; M S Cetron; M M Farley; W S Baughman; R R Facklam; J A Elliott; K A Deaver; R F Breiman
Journal:  N Engl J Med       Date:  1995-08-24       Impact factor: 91.245

View more
  5 in total

1.  Sentinel surveillance as an alternative approach for monitoring antibiotic-resistant invasive pneumococcal disease in Washington State.

Authors:  D B Jernigan; L Kargacin; A Poole; J Kobayashi
Journal:  Am J Public Health       Date:  2001-01       Impact factor: 9.308

2.  Amino acid repetitions in the dihydropteroate synthase of Streptococcus pneumoniae lead to sulfonamide resistance with limited effects on substrate K(m).

Authors:  Y Haasum; K Ström; R Wehelie; V Luna; M C Roberts; J P Maskell; L M Hall; G Swedberg
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

3.  High prevalence of penicillin-nonsusceptible Streptococcus pneumoniae at a community hospital in Oklahoma.

Authors:  R L Moolenaar; R Pasley-Shaw; J R Harkess; A Lee; J M Crutcher
Journal:  Emerg Infect Dis       Date:  2000 May-Jun       Impact factor: 6.883

4.  A novel multiresistant Streptococcus pneumoniae serogroup 19 clone from Washington State identified by pulsed-field gel electrophoresis and restriction fragment length patterns.

Authors:  V A Luna; D B Jernigan; A Tice; J D Kellner; M C Roberts
Journal:  J Clin Microbiol       Date:  2000-04       Impact factor: 5.948

5.  Tracking drug-resistant Streptococcus pneumoniae in Oregon: an alternative surveillance method.

Authors:  A E Chin; K Hedberg; P R Cieslak; M Cassidy; K R Stefonek; D W Fleming
Journal:  Emerg Infect Dis       Date:  1999 Sep-Oct       Impact factor: 6.883

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.